2023 World Conference on Lung Cancer (Posters)-EP11.01. A Multicenter Study of the Association between TTF-1 and Immunochemotherapy in Lung Adenocarcinoma

EP11.01. A Multicenter Study of the Association between TTF-1 and Immunochemotherapy in Lung Adenocarcinoma - PDF(Abstract)

Back to course

Pdf Summary

This abstract highlights the findings of a multicenter study on the association between thyroid transcription factor-1 (TTF-1) and the outcome of immunochemotherapy in lung adenocarcinoma. TTF-1 is known as a good prognostic factor for non-small-cell lung carcinoma, but its role in immunochemotherapy outcomes is not well understood. <br /><br />The study included 95 patients with lung adenocarcinoma who were treated with immunochemotherapy. Tumor samples were re-diagnosed and TTF-1 expression was assessed using immunohistochemical staining. TTF-1 scoring was based on staining intensity and the percentage of positive cells.<br /><br />The results showed that the positivity rate of TTF-1 was 61.1%. Patients with TTF-1 negative had a significantly higher ratio of programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) 1%. The median progression-free survival (PFS) was significantly longer in patients with TTF-1 positive compared to negative. Specifically, patients treated with pemetrexed and TTF-1 positive had a significantly longer PFS than those with TTF-1 negative. On the other hand, the PFS for patients treated with taxane and TTF-1 negative was not inferior to those with TTF-1 positive. Patients with PD-L1 TPS 1% and TTF-1 scoring of 0 had a significantly worse PFS.<br /><br />The authors conclude that TTF-1 may be a good prognostic factor for pemetrexed-based immunochemotherapy in lung adenocarcinoma. They suggest that TTF-1 staining could be used to develop more optimal treatments for this type of cancer.

Asset Subtitle

Nanami Yamasaki

Meta Tag

Speaker Nanami Yamasaki

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

Thyroid transcription factor-1

TTF-1

lung adenocarcinoma

immunochemotherapy

prognostic factor

immunohistochemical staining

PD-L1

tumor proportion score

progression-free survival

pemetrexed-based immunochemotherapy